|IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade|
M Ayers, J Lunceford, M Nebozhyn, E Murphy, A Loboda, DR Kaufman, ...
The Journal of clinical investigation 127 (8), 2930-2940, 2017
|Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes|
R Cristescu, J Lee, M Nebozhyn, KM Kim, JC Ting, SS Wong, J Liu, ...
Nature medicine 21 (5), 449-456, 2015
|Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy|
R Cristescu, R Mogg, M Ayers, A Albright, E Murphy, J Yearley, X Sher, ...
Science 362 (6411), 2018
|Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes|
G Garcia-Manero, H Yang, C Bueso-Ramos, A Ferrajoli, J Cortes, ...
Blood, The Journal of the American Society of Hematology 111 (3), 1060-1066, 2008
|Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer|
ST Kim, R Cristescu, AJ Bass, KM Kim, JI Odegaard, K Kim, XQ Liu, ...
Nature medicine 24 (9), 1449-1458, 2018
|Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma|
Z Kan, H Zheng, X Liu, S Li, TD Barber, Z Gong, H Gao, K Hao, ...
Genome research 23 (9), 1422-1433, 2013
|Analysis of genomic targets reveals complex functions of MYC|
JH Patel, AP Loboda, MK Showe, LC Showe, SB McMahon
Nature Reviews Cancer 4 (7), 562-568, 2004
|Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study|
E Galanis, KA Jaeckle, MJ Maurer, JM Reid, MM Ames, JS Hardwick, ...
Journal of clinical oncology 27 (12), 2052, 2009
|EMT is the dominant program in human colon cancer|
A Loboda, MV Nebozhyn, JW Watters, CA Buser, PM Shaw, PS Huang, ...
BMC medical genomics 4 (1), 1-10, 2011
|Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors|
I Krop, T Demuth, T Guthrie, PY Wen, WP Mason, P Chinnaiyan, ...
Journal of clinical oncology 30 (19), 2307-2313, 2012
|Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors|
V Kumar, L Donthireddy, D Marvel, T Condamine, F Wang, ...
Cancer cell 32 (5), 654-668. e5, 2017
|Functional genomics identifies therapeutic targets for MYC-driven cancer|
M Toyoshima, HL Howie, M Imakura, RM Walsh, JE Annis, AN Chang, ...
Proceedings of the National Academy of Sciences 109 (24), 9545-9550, 2012
|Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma|
L Kari, A Loboda, M Nebozhyn, AH Rook, EC Vonderheid, C Nichols, ...
The Journal of experimental medicine 197 (11), 1477-1488, 2003
|Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.|
A Ribas, C Robert, FS Hodi, JD Wolchok, AM Joshua, WJ Hwu, JS Weber, ...
Journal of Clinical Oncology 33 (15_suppl), 3001-3001, 2015
|Transcriptional architecture of the primate neocortex|
A Bernard, LS Lubbers, KQ Tanis, R Luo, AA Podtelezhnikov, EM Finney, ...
Neuron 73 (6), 1083-1099, 2012
|Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling|
D Coppola, M Nebozhyn, F Khalil, H Dai, T Yeatman, A Loboda, JJ Mulé
The American journal of pathology 179 (1), 37-45, 2011
|Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma|
VR Fantin, A Loboda, CP Paweletz, RC Hendrickson, JW Pierce, JA Roth, ...
Cancer research 68 (10), 3785-3794, 2008
|Comparative expression pathway analysis of human and canine mammary tumors|
P Uva, L Aurisicchio, J Watters, A Loboda, A Kulkarni, J Castle, ...
BMC genomics 10 (1), 1-20, 2009
|A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors|
A Loboda, M Nebozhyn, R Klinghoffer, J Frazier, M Chastain, W Arthur, ...
BMC medical genomics 3 (1), 1-11, 2010
|Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing|
SS Wong, KM Kim, JC Ting, K Yu, J Fu, S Liu, R Cristescu, M Nebozhyn, ...
Nature communications 5 (1), 1-12, 2014